American Society of Hirudotherapy

Plantar Warts (Verruca Plantaris, Refractory)

Highly investigational use for refractory plantar warts (HPV-mediated) after cryotherapy and salicylic acid failure; very limited anecdotal evidence.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for plantar warts (verruca plantaris). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
What evidence exists?
Tier C (investigational). Anecdotal only. Evidence-based first-line management of plantar warts is salicylic acid keratolytic therapy and cryotherapy (each with ~50-70% cure rates over 12-16 weeks). Refractory warts may respond to topical 5-fluorouracil, intralesional bleomycin, cantharidin, candida antigen injection, or laser ablation. Many plantar warts also resolve spontaneously over 12-24 months.
Main risks
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Spread of HPV to surrounding skin from disturbing the wart surface
  • Painful prolonged bleeding from a thick keratinized plantar surface that does not seal easily
Who should not consider this
  • Patients with diabetes, peripheral arterial disease, or peripheral neuropathy (high foot-ulcer risk)
  • Patients whose warts have not had a proper trial of salicylic acid, cryotherapy, or other standard therapy
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with anemia
  • People with an active infection at the planned application site
  • Patients who are pregnant (leech therapy is not done during pregnancy) or breastfeeding (discuss it with your doctor)
What to ask your clinician
  • Have I tried salicylic acid for at least 12 weeks?
  • Have I tried cryotherapy for 2-3 sessions?
  • Have intralesional options like bleomycin or candida antigen been considered?
  • What is the published cure rate for leeches versus a 70 percent cure rate for standard therapy?
  • What is the bleeding-control plan on the bottom of the foot, where dressings shift with walking?
  • How will viral spread to other foot skin be prevented?
When to seek urgent care
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Inability to bear weight on the foot due to pain or new wound
  • Spreading streaks of redness up the foot or leg

What this does NOT mean

  • It does not mean leech therapy is FDA-cleared for plantar warts — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace standard therapy: salicylic acid, cryotherapy, and (for refractory cases) intralesional injections or laser.
  • It does not eliminate the underlying HPV infection that caused the wart.
  • It does not prevent recurrence at the same or new sites.
  • It does not have controlled-trial evidence for this indication.

Clinical Profile

Category
Dermatological
ICD-10
B07.0, B07.9
Safety tier
Low

Evidence Summary

Plantar warts are HPV-mediated benign epithelial proliferations conventionally treated with topical salicylic acid (~60% efficacy) and cryotherapy (~50% efficacy), with second-line options including intralesional bleomycin or candida antigen, pulsed dye laser, or surgical paring with cantharidin. Direct evidence for leech therapy is limited to a single case report (Aktas and Hamidi, 2019, Clin Exp Dermatol) describing clearance of a longstanding giant plantar wart after medicinal leech application in an immunosuppressed patient; this is grade D anecdotal evidence, not a case series, and the mechanism is unclear (possible local immune stimulation). Most plantar warts resolve spontaneously over 1-2 years.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Plantar warts are not named in the books; the closest in Baskova and Isakhanyan is a viral skin lesion with pointed warts (condylomata acuminata), which they list among the dermatological indications for hirudotherapy[B1].
  • They retell observations by Ya. I. Bondarevsky and I. Ya. Bondarevsky (1995) and Ya. I. Bondarevsky (1999): when hirudotherapy was included in the treatment of patients with a viral skin lesion, pointed warts resolved faster, except for eruptions at the external opening of the urethra; what they were compared with, how many patients there were and what else was in the complex is not clear from the text[B1].
  • In another place in the book, Bondarevsky (1998) is named as having used hirudotherapy within a complex of treatment measures, among other things, in papillomavirus infection of the genitals; according to the book, good results were obtained, and inflammatory processes and skin rash decreased[B1].
  • Michalsen et al. do not write about warts or papillomavirus skin lesions; of the viral skin diseases they name only shingles (herpes zoster), which is not related to warts[B3].
  • Among the contraindications, Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemias, low blood pressure and acute vascular insufficiency (shock, collapse, fainting), emaciation, concurrent use of anticoagulants (especially long-term and daily), concurrent use of alcohol, individual intolerance and an extremely negative attitude of the patient toward leeches, and at high body temperature they advise refraining from leeches[B1].
  • Flecken and Michalsen, in the chapter on contraindications, call hemophilia and the use of anticoagulants an absolute contraindication, and in anemia and bone-marrow suppression, according to them, any treatment involving blood removal is generally contraindicated; aspirin and clopidogrel are not contraindications in themselves, but at the first session they advise reducing the number of leeches and asking the patient about a tendency to bleed[B3].
  • In the appendix of Michalsen et al. (patient information and consent form), hirudotherapy is not performed, among other conditions, in blood diseases, acute gastric ulcer or erosive gastritis, immune deficiency (AIDS, chemotherapy), severe chronic diseases (advanced cancer, dialysis), a history of poor wound healing (for example, with poorly controlled diabetes, obesity and long-term cortisone treatment), known allergy to the active substances in leech saliva, and a tendency to keloids or scarring; the same document asks the patient not to use perfumed lotions, shower gels, medicinal ointments and oils on the day before and on the day of the procedure[B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Mosaic warts covering >5 cm area (immune-targeted therapy preferred)
  • Diabetic foot or peripheral neuropathy
  • Immunocompromise predisposing to HPV proliferation
  • Suspected verrucous carcinoma (biopsy required)

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.